Does Positive KT-621 Atopic Dermatitis Data Change The Bull Case For Kymera Therapeutics (KYMR)? [Yahoo! Finance]
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
Kymera Therapeutics (KYMR) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside [Yahoo! Finance]